Rachitskaya: Archway found incidence of retinal fluid at Week 96 was generally comparable across treatment arms

SAP Partner | <b>Cleveland Clinic</b>

At the recent ASRS meeting in New York, Aleksandra Rachitskaya, MD, of the Cleveland Clinic Cole Eye Institute, presented End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD.

At the recent ASRS meeting in New York, Aleksandra Rachitskaya, MD, of the Cleveland Clinic Cole Eye Institute, presented End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD. The goal, she said, was to describe the relationship between retinal fluid and vision outcomes over 96 weeks in the Archway trial of the Port Delivery System with ranibizumab in neovascular age-related macular degeneration (nAMD).